NIH's RECOMBINANT DNA ADVISORY COMMITTEE SHOULD CONTINUE TO REVIEW GENE THERAPY AS GERMLINE AND SOCIETAL ISSUES ARISE, RAC AD HOC GROUP CONCURS
Issues related to germline therapy warrant the continued existence of the Recombinant DNA Advisory Committee, ad hoc RAC review committee members agreed at their second meeting March 8 on the National Institutes of Health campus.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth